A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone

Molecular Cancer Therapeutics

Volumn 11, Issue 10, 2012, Pages 2096-2104

  Ayan, Diana ^a   Maltais, René ^a   Roy, Jenny ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

17 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3 (2 BROMOETHYL) 16 BETA ( 3 CARBAMOYLBENZYL) 17 BETA HYDROXY 1,3,5(10) ESTRATRIEN; ESTRONE; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; ESTRONE; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84867422422     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0299     Document Type: Article

References (49)

1. Jansson A. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol 2009;114:64-7.
2. Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988;9:295-318.
3. Penning TM. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Hum Reprod Update 2003;9:193-205. (Pubitemid 36827058)
4. Hyndman D, Bauman DR, Heredia VV, Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003;143-144:621-31. (Pubitemid 36246464)
5. Moeller G, Adamski J. Multifunctionality of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006;248:47-55.
6. Meier M, Moller G, Adamski J. Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease. Ann N Y Acad Sci 2009;1155:15-24.
7. Mindnich R, Moller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004;218:7-20. (Pubitemid 38578426)
8. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207-21. (Pubitemid 351611954)
9. Poirier D. New cancer drugs targeting the biosynthesis of estrogens and androgens. Drug Devel Res 2008;69:304-18.
10. Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. Cell Tissue Res 2005;320:393-8. (Pubitemid 40884140)
11. Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 8 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. J Histochem Cytochem 2005;53:1257-71. (Pubitemid 41331124)
12. Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 7 17beta-hydroxysteroid dehydrogenase in mouse tissues. In situ hybridization studies. J Steroid Biochem Mol Biol 2005;93:49-57. (Pubitemid 40312733)
13. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581-7. (Pubitemid 26019342)
14. Brozic P, Lanisnik Risner T, Gobec S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr Med Chem 2008;15:137-50.
15. Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM,et al. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 2006;248:199-203.
16. Simard J, Vincent A, Duchesne R, Labrie F. Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs. Mol Cell Endocrinol 1988;55:233-42. (Pubitemid 18055213)
17. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001;94:685-9. (Pubitemid 33035688)
18. Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, Soini Y, et al. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 2004;64:7604-9. (Pubitemid 39372106)
19. + breast cancer cell proliferation induced by estrone. Bioorg Med Chem 2008;16:1849-60.
20. Poirier D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Curr Med Chem 2003;10:453-77.
21. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 2006;13:129-36.
22. Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, Tutill HJ, et al. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Chem Med Chem 2006;1:464-81.
23. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, et al. 17beta-hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 2008;122:1931-40. (Pubitemid 351441181)
24. Berube M, Poirier D. Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and Sonogashira coupling reactions. Org Lett 2004;6:3127-30. (Pubitemid 39233136)
25. Ciobanu LC, Poirier D. Synthesis of libraries of 16beta-aminopropyl estradiol derivatives for targeting two key steroidogenic enzymes. Chem Med Chem 2006;1:1249-59. (Pubitemid 44786931)
26. Poirier D, Boivin RP, Tremblay MR, Berube M, Qiu W, Lin SX. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase. J Med Chem 2005;48:8134-47. (Pubitemid 43032522)
27. Poirier D, Ciobanu LC, Berube M. A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives. Bioorg Med Chem Lett 2002;12:2833-8. (Pubitemid 35266744)
28. Tremblay MR, Poirier D. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation. J Steroid Biochem Mol Biol 1998;66:179-91. (Pubitemid 28401692)
29. Poirier D. Contribution to the development of inhibitors of 17beta-hydroxysteroid dehydrogenase types 1 and 7: Key tools for studying and treating estrogen-dependent diseases. J Steroid Biochem Mol Biol 2011;125:83-94.
30. Maltais R, Ayan D, Poirier D. Crucial role of a 3-bromoethyl side-chain in removing the undesirable estrogenic activity of potent 17β- hydroxysteroid dehydrogenase type 1 inhibitor 16β-(m-carbamoybenzyl) estradiol. ACS Med Chem Lett 2011;2:678-81.
31. Tremblay MR, Boivin RP, Luu-The V, Poirier D. Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol. J Enzyme Inhib Med Chem 2005;20:153-63. (Pubitemid 40645506)
32. Cadot C, Laplante Y, Kamal F, Luu-The V, Poirier D. C6-(N,N-butyl-methyl- heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation. Bioorg Med Chem 2007;15:714-26. (Pubitemid 44880729)
33. Levesque C, Merand Y, Dufour JM, Labrie C, Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 1991;34:1624-30.
34. Davis DD, Díaz-Cruz ES, Landini S, Kim YW, Brueggemeier RW. Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol 2008;108:23-31. (Pubitemid 351173827)
35. Arcaro KF, Yi L, Seegal RF, Vakharia DD, Yang Y, Spink DC, et al. 2,2′,6,6′-Tetrachlorobi-phenyl is estrogenic in vitro and in vivo. J Cell Biochem 1999;72:94-102.
36. Poirier D, Maltais R, Roy J, inventors; Université Laval, assignee. Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10. International patent application PCT/CA2012/00316 filed March 26, 2012.
37. Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F. Additive inhibitory effects of an androgen and the estrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 1991;51:3131-5.
38. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, Thole H. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol 2006;248:109-13.
39. Husen B, Huhtinen K, Saloniemi T, Messinger J, Thole HH, Poutanen M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006;147:5333-9. (Pubitemid 44790588)
40. Messinger J, Hirvela L, Husen B, Kangas L, Koskimies P, Pentikainen O, et al. New inhibitors of 17beta-hydroxysteroid dehydrogenase type1. Mol Cell Endocrinol 2006;248:192-8.
41. Kramer C. Extension of multiple range tests to group with unique numbers of replications. Biometrics 1956;12:307-10.
42. Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 1997;70:639-43. (Pubitemid 27158440)
43. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, et al. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 1979;15:659-70. (Pubitemid 9198534)
44. Peltoketo H, Luu-The V, Simard J, Adamski J. 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 1999;23:1-11. (Pubitemid 29369554)
45. Nokelainen P, Puranen T, Peltoketo H, Orava M, Vihko P, Vihko R. Molecular cloning of mouse 17 beta-hydroxysteroid dehydrogenase type 1 and characterization of enzyme activity. Eur J Biochem 1996;236:482-90. (Pubitemid 26098832)
46. Pelletier G, Luu-The V, Li S, Ren L, Labrie F. Localization of 17beta-hydroxysteroid dehydrogenase type 1 mRNA in mouse tissues. J Mol Endocrinol 2004;33:459-65. (Pubitemid 39429569)
47. Moller G, Husen B, Kowalik D, Hirvela L, Plewczynski D, Rychlewski L, et al. Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1. PLoS One 2010;5:e10969.
48. Poirier D. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin Ther Pat 2010;20:1123-45.
49. Poulin R, Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 1986;46:4933-7. (Pubitemid 16008241)